A phase IIa study of Prexigebersen in accelerated and blast phase chronic myeloid leukemia (CML) patients.

Trial Profile

A phase IIa study of Prexigebersen in accelerated and blast phase chronic myeloid leukemia (CML) patients.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Dasatinib (Primary) ; Prexigebersen (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2018 New trial record
    • 29 Dec 2017 According to a Bio-Path Holdings media release, the trial is being conducted at The University of Texas MD Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top